Physician profile
Nathan Benjamin Green
NPI 1679563936
$9,957.63
in general payments reported to CMS, 2019-2025
72 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $636 · 2021: $1,336 · 2022: $1,821 · 2023: $1,644 · 2024: $1,575 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900 · Education: $53.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,899.75 |
| Education | $53.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $871.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $672.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $609.01 | 2019-2025 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $578.64 | 2019-2025 | |
| Abbvie INC. | $524.30 | 2019-2025 | |
| Seagen INC. | $467.57 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $461.44 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $439.88 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Genentech USA, INC. | $429.03 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Eisai INC. | $328.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.58 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $317.13 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Genzyme Corporation | $282.34 | 2019-2025 | |
| Celgene Corporation | $266.22 | 2021-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $246.45 | 2019-2023 | Nplate, Xgeva, Vectibix |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.